CD4(+) T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

As a widely studied adoptive treatment method, CIK (cytokine-induced killer cells) treatment has shown clinical benefits in many clinical trials on non-small cell lung cancer. As a heterogeneous cell population, however, CIK cells have a strong instability and individual differences in their efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shaochuan, Meng, Yuan, Liu, Liang, Lv, Yingge, Yu, Wenwen, Liu, Ting, Wang, Limei, Mu, Di, Zhou, Qiuru, Liu, Min, Ren, Yulin, Zhang, Dong, Li, Baihui, Sun, Qian, Ren, Xiubao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076680/
https://www.ncbi.nlm.nih.gov/pubmed/35523765
http://dx.doi.org/10.1038/s41419-022-04882-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076680/
https://www.ncbi.nlm.nih.gov/pubmed/35523765
http://dx.doi.org/10.1038/s41419-022-04882-x

Ejemplares similares